These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
604 related articles for article (PubMed ID: 23153075)
1. Erectile dysfunction diagnosis and treatment as a means to improve medication adherence and optimize comorbidity management. Scranton RE; Goldstein I; Stecher VJ J Sex Med; 2013 Feb; 10(2):551-61. PubMed ID: 23153075 [TBL] [Abstract][Full Text] [Related]
2. Role of phosphodiesterase type 5 inhibitors for lower urinary tract symptoms. Miller MS Ann Pharmacother; 2013 Feb; 47(2):278-83. PubMed ID: 23386068 [TBL] [Abstract][Full Text] [Related]
3. Treating erectile dysfunction and central neurological diseases with oral phosphodiesterase type 5 inhibitors. Review of the literature. Lombardi G; Nelli F; Celso M; Mencarini M; Del Popolo G J Sex Med; 2012 Apr; 9(4):970-85. PubMed ID: 22304626 [TBL] [Abstract][Full Text] [Related]
6. A 6-month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Middle Eastern and North African men with erectile dysfunction. El-Meliegy A; Rabah D; Al-Mitwalli K; Mostafa T; Hussein T; Istarabadi M; Lei Y; Gurbuz S Curr Med Res Opin; 2013 Jun; 29(6):707-17. PubMed ID: 23540436 [TBL] [Abstract][Full Text] [Related]
7. A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with α-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Gacci M; Corona G; Salvi M; Vignozzi L; McVary KT; Kaplan SA; Roehrborn CG; Serni S; Mirone V; Carini M; Maggi M Eur Urol; 2012 May; 61(5):994-1003. PubMed ID: 22405510 [TBL] [Abstract][Full Text] [Related]
8. 10-Year analysis of adverse event reports to the Food and Drug Administration for phosphodiesterase type-5 inhibitors. Lowe G; Costabile RA J Sex Med; 2012 Jan; 9(1):265-70. PubMed ID: 22023666 [TBL] [Abstract][Full Text] [Related]
9. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. Mulhall JP; McLaughlin TP; Harnett JP; Scott B; Burhani S; Russell D J Sex Med; 2005 Nov; 2(6):848-55. PubMed ID: 16422809 [TBL] [Abstract][Full Text] [Related]
10. Comparison of the first intake of vardenafil and tadalafil in patients with diabetic neuropathy and diabetic erectile dysfunction. Kamenov ZA J Sex Med; 2011 Mar; 8(3):851-64. PubMed ID: 21143421 [TBL] [Abstract][Full Text] [Related]
11. 2009 update on phosphodiesterase type 5 inhibitor therapy part 2: updates on optimal utilization for sexual concerns and rare toxicities in this class. Shindel AW J Sex Med; 2009 Sep; 6(9):2352-64; quiz 2365-6. PubMed ID: 19735356 [TBL] [Abstract][Full Text] [Related]
12. A 6 month, prospective, observational study of PDE5 inhibitor treatment persistence and adherence in Latin American men with erectile dysfunction. Rubio-Aurioles E; Reyes LA; Borregales L; Cairoli C; Sorsaburu S Curr Med Res Opin; 2013 Jun; 29(6):695-706. PubMed ID: 23540375 [TBL] [Abstract][Full Text] [Related]
13. Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. Wang R; Burnett AL; Heller WH; Omori K; Kotera J; Kikkawa K; Yee S; Day WW; DiDonato K; Peterson CA J Sex Med; 2012 Aug; 9(8):2122-9. PubMed ID: 22759639 [TBL] [Abstract][Full Text] [Related]
14. Erectile dysfunction and the drugs to treat it. In many cases, medications are all a man needs to stay sexually active. Harv Health Lett; 2014 May; 39(7):7. PubMed ID: 25073193 [No Abstract] [Full Text] [Related]
15. Improvement in sexual quality of life of the female partner following vardenafil treatment of men with erectile dysfunction: a randomized, double-blind, placebo-controlled study. Martín-Morales A; Graziottin A; Jaoudé GB; Debruyne F; Buvat J; Beneke M; Neuser D J Sex Med; 2011 Oct; 8(10):2831-40. PubMed ID: 21679304 [TBL] [Abstract][Full Text] [Related]
16. Emotional changes in men treated with sildenafil citrate for erectile dysfunction: a double-blind, placebo-controlled clinical trial. Moncada I; Martínez-Jabaloyas JM; Rodriguez-Vela L; Gutiérrez PR; Giuliano F; Koskimaki J; Farmer IS; Renedo VP; Schnetzler G J Sex Med; 2009 Dec; 6(12):3469-77. PubMed ID: 19796051 [TBL] [Abstract][Full Text] [Related]
17. Therapy of ED: PDE-5 Inhibitors. Shabsigh R Endocrine; 2004; 23(2-3):135-41. PubMed ID: 15146092 [TBL] [Abstract][Full Text] [Related]
18. PDE5 inhibitor treatment persistence and adherence in Brazilian men: post-hoc analyses from a 6-month, prospective, observational study. Cairoli C; Reyes LA; Henneges C; Sorsaburu S Int Braz J Urol; 2014; 40(3):390-9. PubMed ID: 25010306 [TBL] [Abstract][Full Text] [Related]
19. Management of ED under the "severe distress" criteria in the NHS: a real-life study. Mohee A; Bretsztajn L; Storey A; Eardley I J Sex Med; 2014 Apr; 11(4):1056-1062. PubMed ID: 24382018 [TBL] [Abstract][Full Text] [Related]
20. Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Doggrell SA Expert Opin Pharmacother; 2005 Jan; 6(1):75-84. PubMed ID: 15709885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]